{"organizations": [], "uuid": "4436f8710a5a6382bf887b6a5620eeb5667846f5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/14/business-wire-quanterix-corporation-releases-operating-results-for-fourth-quarter-and-fiscal-year-2017.html", "country": "US", "domain_rank": 767, "title": "Quanterix Corporation Releases Operating Results for Fourth and Fiscal Year 2017", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-14T23:05:00.000+02:00", "replies_count": 0, "uuid": "4436f8710a5a6382bf887b6a5620eeb5667846f5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/14/business-wire-quanterix-corporation-releases-operating-results-for-fourth-quarter-and-fiscal-year-2017.html", "ord_in_thread": 0, "title": "Quanterix Corporation Releases Operating Results for Fourth and Fiscal Year 2017", "locations": [], "entities": {"persons": [{"name": "kevin hrusovsky", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "lexington", "sentiment": "none"}], "organizations": [{"name": "quanterix corporation", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Revenue at high end of range previously provided\nSuccessful IPO completed in December 2017\nLaunch of SR-X in Q4, earlier than planned\nLEXINGTON, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ:QTRX) , a company digitizing biomarker analysis to advance the science of precision health, reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously announced in January 2018.\n“2017 was an important year for Quanterix, and I am pleased to report progress on a number of pivotal focus areas,”said Chief Executive Officer, President and Chairman, Kevin Hrusovsky. “In our first quarter as a public company, we continued to grow revenues, scale the company for future success and make inroads launching digital biomarker technologies into neurology, oncology and infectious disease application areas.”\nFourth Quarter Financial Highlights\nKey financial results for the fourth quarter are shown below:\nQ4 revenue of $6.6M versus prior year Q4 of $6.7M, a decrease of 1%. Q4 2016 includes $1.8M in non-recurring revenue recognized in connection with a license; excluding that the revenue growth was 35%. Q4 product revenue totaled $4.1M versus prior year of $3.2M; Consumables drove this performance. Product revenue included the sale of five of the newly launched SR-X benchtop reader. This launch was more than a quarter ahead of schedule. Q4 Service and Other Revenue totaled $2.3M versus prior year of $1.7M, an increase of 34%. Strong liquidity position at year-end with $79.7M of cash and $9.4M of debt. Successfully closed its initial public offering of 4,916,480 shares of common stock at a public offering price of $15.00 per share, and received $73.7M in gross proceeds from the offering, prior to deducting underwriting discounts and commissions, and offering expenses payable by the company. The shares began trading on The NASDAQ Global Market on December 7, 2017 under the ticker symbol “QTRX.” Expanded market opportunity through the launch of the new SR-X Ultra-Sensitive Biomarker Detection System™ , opening the door for researchers to access ultra-sensitive protein and nucleic acid detection capabilities in a more compact and affordable system. The SR-X was made commercially available in December 2017 and Quanterix received 16 orders for the new system in Q4, with limited marketing support behind the new launch.\n2017 and Recent Business Highlights\nFull year 2017 revenue of $22.9M, the high end of the previously provided guidance of $22.5-22.9M, versus full year 2016 revenue of $17.6M, an increase of 30% year-over-year; excluding the 2016 non-recurring revenue recognized in connection with a license, revenue growth was 45%. Impressive full year revenue performance in consumables (70% increase) and Accelerator (57% increase); Accelerator also carried forward significant backlog into 2018. Reinforced leadership position in the market through presentations from Kevin Hrusovsky, Chief Executive Officer, President and Chairman, at The Leerink Partners 7 th Annual Global Healthcare Conference, The 36 th Annual J.P. Morgan Healthcare Conference , Innovate Conference 2017 , World Medical Innovation Forum , Second Annual Brain Trust: Pathways to Innovation , Second Annual Powering Precision Health Summit , and participating in the Fourth and Fifth Annual Super Bowl Brain Health Summits . Expanded the Second Annual Powering Precision Health Summit across neurology, oncology and infectious disease application areas. The summit was impactful with over 50 presentations from speakers credited with over 6000 peer reviewed publications. The conference attracted over 500 attendees from around the world, and helped to underscore the importance of Quanterix’ technologies toward enabling personalized medicine and precision health. Expanded multiplexing immunoassay menu and accelerated entry into pharmaceutical services with a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory through the January 2018 acquisition of Aushon BioSystems, an innovator in protein detection solutions. The Company now has access to the services of the Laboratory Director of Aushon’s CLIA-certified laboratory. Strengthened its management team with the recent appointments of Dr. Dawn Mattoon as SVP of Strategic Marketing and Assay Technologies, who will lead marketing efforts for Quanterix and oversee assay development and kit manufacturing, two areas of critical importance to Quanterix’ rapidly growing customer base; and Yvan Sergeant as VP of European Commercial Operations, who will be responsible for expanding Quanterix’ business operations in Europe, and help in the establishment of a European-based Accelerator Lab. The Company also expanded its relationship with neurology industry leader, Dr. Andreas Jeromin, who will serve as Scientific and Medical Advisor.\nConference Call\nIn conjunction with this announcement, Quanterix Corporation will host a conference call on March 14, 2018, at 4:30 p.m., EDT to discuss the Company’s financial results and business outlook. To access this call, dial (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following password: 5079049.\nA live webcast will be accessible on the Investors section of Quanterix’ website: http://www.quanterix.com . The webcast will be available on the Company’s website for one year following completion of the call.\nFinancial Highlights (in thousands)\nQuanterix Statement of Operations\nQ4 2017 Q4 2016 Fiscal 2017 Fiscal 2016 Product revenue 4,068 3,166 14,124 10,601 Service and other revenue 2,252 1,682 7,676 5,012 Collaboration revenue 269 1,831 1,074 1,972 Total revenue 6,589 6,679 22,874 17,585 Cost of product revenue 2,169 1,798 7,742 6,299 Cost of service revenue 1,539 918 5,145 3,163 Cost of collaboration revenue - 375 - 375 Research and development 3,927 6,801 16,304 16,993 Selling, General and administrative 6,046 3,600 19,688 12,466 Total operating expenses 13,682 13,493 48,879 39,297 Interest expense, net (217 ) (286 ) (952 ) (1,298 ) Other income (expense), net (73 ) (215 ) (62 ) (164 ) Net loss (7,382 ) (7,315 ) (27,019 ) (23,173 ) Quanterix balance sheet 12/31/17 12/31/16 Cash 79,682 29,671 AR 5,599 3,917 Inventory 3,571 1,528 Prepaid and other 400\n127\nTotal current assets 89,252 35,243 Property and equipment, net 1,874 1,223 Other non-current assets 652\n651\nTotal assets 91,779 37,117 Accounts payable/accrued expenses 9,736 6,628 Deferred revenue 4,942 3,428 Current portion of long term debt 5,036\n899\nTotal current liabilities 19,714 10,955 Preferred stock warrant liability 0 2,802 Deferred revenue, net of current 1,709 328 Long term debt 4,346 9,344 Other non-current liabilities 143\n212\nTotal liabilities 25,913 23,641 Redeemable convertible preferred stock 128,585 Total stockholders equity (deficit) 65,866\n(115,109\n)\nTotal liabilities and Stockholders Equity 91,779 37,117 About Quanterix\nQuanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com .\nForward-Looking Statements\nThis press release contains within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"may,\" \"will,\" \"expect,\" \"plan,\" \"anticipate,\" \"estimate,\" \"intend\" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify . Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the \"Risk Factors\" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any contained herein to reflect any change in expectations, even as new information becomes available.\nStatement on Use of Non-GAAP Financial Measures\nTo supplement the Company’s financial statements presented on a GAAP basis, the Company discloses non-GAAP revenue growth that excludes $1.8M in non-recurring revenue recognized in 2016 in connection with a license. Management uses this non-GAAP measure to evaluate the Company’s operating performance. Management believes that such measure is important in comparing current results with prior period results, and is useful to investors and financial analysts in assessing the Company’s operating performance. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP.\nReconciliation of non-GAAP Revenue Growth\n(in thousands)\n(unaudited)\n2017 2016 % Change Year ended December 31, Total revenue $22,874 $17,585 30% Subtract Non-recurring license revenue\n— 1,800 Non-GAAP total revenue $22,874 $15,785 45% 2017 2016 % Change Three months ended\nDecember 31,\nTotal revenue $6,589 $6,679 (1%) Subtract Non-recurring license revenue\n— 1,800 Non-GAAP total revenue $6,589 $4,879 35%\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180314006091/en/\nQuanterix, Inc.\nJoseph Driscoll, CFO, 617-301-9495\njdriscoll@quanterix.com\nor\nPAN Communications\nLauren Kaufman, 617-502-4300\nquanterix@pancomm.com\nSource: Quanterix Corporation", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-corporation-present-36th-annual-jp-morgan-healthcare-conference&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=The+36th+Annual+J.P.+Morgan+Healthcare+Conference&index=6&md5=e919da088562309e263e5a13336207c4", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-discuss-precision-cardiovascular-medicine-world-medical&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=World+Medical+Innovation+Forum&index=8&md5=2174392a7f887a5c89bb304dad2c11e9", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.quanterix.com&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=http%3A%2F%2Fwww.quanterix.com&index=13&md5=7333633f2f9410457339061904f8f934", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-participate-second-annual-brain-trust-pathways-innovation&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=Second+Annual+Brain+Trust%3A+Pathways+to+Innovation&index=9&md5=c9ba9f5a32b8155d446605610c6a076a", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20171114006683%2Fen%2FFounder-Precision-Health-Movement-Headline-Smart-Health&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=Innovate+Conference+2017&index=7&md5=c016f840a6647831bf55bcfaebdeccb3", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fsrx&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=SR-X+Ultra-Sensitive+Biomarker+Detection+System%E2%84%A2&index=3&md5=e609a9662c9f66be4dd582a84bc44809", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-present-leerink-partners-7th-annual-global-healthcare-conference&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=The+Leerink+Partners+7th+Annual+Global+Healthcare+Conference%2C&index=5&md5=554faab6f4191ef38c190473912beeee", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.quanterix.com%2F&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=Quanterix+Corporation+%28NASDAQ%3AQTRX%29&index=1&md5=012af37d0a7aafba0a9cca7744977e55", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-participate-fourth-annual-super-bowl-brain-health-summit&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=Super+Bowl+Brain+Health+Summits&index=11&md5=548fb0376f29ade5f59596b25a0a2eb6", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pphsummit.com%2F&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=Powering+Precision+Health+Summit&index=10&md5=de52686eaeec88f76a2c24a5b663ecfa", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=https%3A%2F%2Fwww.quanterix.com&index=14&md5=73c2ae6921a80c4d7d78c0b700567656", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pphsummit.com%2F&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=Powering+Precision+Health+Summit&index=12&md5=2bc2e3888d8eee653771bd7b1caf8617", "http://www.businesswire.com/news/home/20180314006091/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-announces-commercial-availability-new-sr-x-ultra-sensitive&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=commercially+available&index=4&md5=c0b10aaa42e32e43ab684eafc6e959c2", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.quanterix.com%2Fresources%2Fpress-releases%2Fquanterix-corporation-announces-closing-initial-public-offering&esheet=51773379&newsitemid=20180314006091&lan=en-US&anchor=initial+public+offering&index=2&md5=eed2832dbd36a8a71aa396238584e9be"], "published": "2018-03-14T23:05:00.000+02:00", "crawled": "2018-03-15T02:14:59.028+02:00", "highlightTitle": ""}